OXBBissau, Guinea-Bissau - Osvaldo Vieira (Airport Code)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
The orexin binds to two types of receptors, belonging to the class of G protein-coupled receptors: orexin receptor type-1 (OX1R or hypocretin receptor 1) and orexin receptor type-2 (OX2R or hypocretin receptor 2) Both orexin receptors subtypes can bind to OXA and OXB, but with differential affinity; in particular orexin receptor type-1 has a higher affinity for OXA, while orexin receptor type- 2 has equal affinity for either orexin peptide [3,4] (Figure 1).
The consortium will be led by Oxford BioMedica (LON: OXB), with other partners including the Cell and Gene Therapy Catapult, Stratophase and Synthace.
Oxford BioMedica (LON: OXB) and Novartis (VTX: NOVN) have signed an agreement for the commercial and clinical supply of lentiviral vectors, used to generate CTL019 (tisagenlecleucel), as well as other undisclosed Chimeric Antigen Receptor T cell (CAR-T) products, the British company disclosed on Thursday.
Oxford BioMedica plc (LON: OXB) has appointed Stuart Paynter as chief financial officer to succeed Tim Watts, who is retiring from full-time executive roles, the company announced on Tuesday.
25 May 2011 - UK-based gene therapy company Oxford BioMedica (LSE: OXB) announced yesterday that Dr Alex Lewis has been appointed as director of Corporate Activities and Strategy and a member of the senior management team with immediate effect.
23 May 2011 - UK-based gene therapy company Oxford BioMedica plc (LON: OXB) announced that new data from the ongoing Phase I/II trial of ProSavin for the treatment of Parkinson's disease (PD) were presented at the American Society of Gene & Cell Therapy (ASGCT) 14th Annual Meeting held in Seattle, USA by Professor Stephane Palfi, Principal Investigator at the Henri Mondor Hospital in Paris, on 21 May 2011.
22 March 2011 - UK-based gene therapy company Oxford BioMedica plc (LON: OXB) announced yesterday that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the Phase I/IIa clinical development of StarGen, a novel gene-based treatment for Stargardt disease.
21 March 2011 - UK-based biopharmaceutical company Oxford BioMedica plc (LON: OXB) today announced that by mutual agreement, its chairman, Alan Kingsman, will leave the board of Oxford BioMedica at the company's forthcoming Annual General Meeting on 5 May 2011.
31 January 2011 - UK-based gene therapy company Oxford BioMedica plc (LON: OXB) today announced it has agreed to acquire a manufacturing facility based in Oxford, UK, from RecipharmCobra Biologics, the specialist biologics division of Swedish company Recipharm AB, for a purchase price of GBP1.9m (USD3m/EUR2.2m).
<span>20 January 2010 - UK biopharmaceutical company Oxford BioMedica Plc (LON: OXB)</span> <span>said </span><span>todayaA </span><span>thataA its gene therapy </span><span>UshStat </span><span>foraA </span><span>the treatment of</span><span>aA Usher s</span><span>yndrome 1B</span><span>aA </span><span>has received orphan designation from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA, formerly known as EMEA)</span><span>.aA </span>